<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00563862</url>
  </required_header>
  <id_info>
    <org_study_id>L/M-78 to PYH 08/79</org_study_id>
    <secondary_id>HARECCTR0500024</secondary_id>
    <secondary_id>NPC99-02</secondary_id>
    <nct_id>NCT00563862</nct_id>
  </id_info>
  <brief_title>Benefit of Adding Chemotherapy And/Or Modification of Radiotherapy Schedule for Advance Nasopharyngeal Carcinoma (T3-4N0-1M0)</brief_title>
  <official_title>Prospective Randomized Study on Therapeutic Gain Achieved By Chemoradiation And/Or Accelerated Radiation For T3-4N0-1M0 Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Authority, Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hong Kong Nasopharyngeal Cancer Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital Authority, Hong Kong</source>
  <brief_summary>
    <textblock>
      To test the therapeutic ratio of accelerated radiotherapy and/or chemotherapy on locally
      advanced nasopharyngeal carcinoma.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 1999</start_date>
  <completion_date type="Actual">June 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure free survival rate</measure>
    <time_frame>5-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival rate</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complication-free rates</measure>
    <time_frame>5-year</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">465</enrollment>
  <condition>Nasopharyngeal Neoplasms</condition>
  <condition>Carcinoma, Squamous Cell</condition>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional RT</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Accelerated RT</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undifferentiated or non-keratinizing carcinoma

          -  Tumor staged as T3-4 AND N0-1

          -  No evidence of distant metastasis (M0)

          -  Performance status: 0-2

          -  Marrow: WBC &gt;= 4 and platelet = 100

          -  Renal: creatinine clearance = 60

          -  Informed consent

        Exclusion Criteria:

          -  WHO type I squamous cell carcinoma or adenocarcinoma

          -  Age &gt;= 70

          -  Palliative intent or tumor extent mandating AP opposing facio-cervical fields

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in
             situ cervical cancer, or other cancer for which the patient has been disease-free for
             5 years

          -  Previous radiotherapy (except non-melanomatous skin cancers outside the intended RT
             treatment volume

          -  Previous chemotherapy

          -  Patient is pregnant or lactating
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Anne WM Lee, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pamela Youde Nethersole Eastern Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tuen Mun Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.ekg.org.hk/HAREC-CTR/RegistryDisplay2.jsp?HARECID=HARECCTR0500024</url>
    <description>HAREC Clinical Trial Registry</description>
  </link>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 23, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 26, 2007</study_first_posted>
  <last_update_submitted>June 14, 2011</last_update_submitted>
  <last_update_submitted_qc>June 14, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 16, 2011</last_update_posted>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>T3-4N0-1M0</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

